Identification of biomarkers and key pathways in synovial sarcoma cells exposed to anlotinib by integrating bioinformatics analysis and experimental validation.

ABSTRACT:

Objective

To identify potential biomarkers, key pathways and modules following the exposure of synovial sarcoma (SS) cells to anlotinib.

Methods

In the current study, we integrated multiple bioinformatics methods to identify the hub genes and key pathways associated with the effects of anlotinib treatment in SS cells. In addition, we used reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR) to validate the expression levels of the identified hub genes in SS cells treated with anlotinib.

Results

In total, 183 differentially expressed genes (DEGs) were identified, of which 47 were upregulated and 136 were downregulated. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses showed that the DEGs were predominant

SUBMITTER: Liu X 

PROVIDER: S-EPMC9641485 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature